App-Quantinova.ai

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute lymphoblastic leukemia

N/A

Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens

Rashmi Kanagal-Shamanna - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

TP53

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Jeffery J Auletta - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Jeffery J Auletta - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Comparison of Reduced-Intensity Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Patients 50 Years or Older

Koji Kawamura - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

fludarabine tablet

Impact of Total Body Irradiation on Successful Neutrophil Engraftment in Unrelated Bone Marrow or Cord Blood Transplantation

Hideki Nakasone - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

fludarabine tablet

REG3A Polymorphism Is Associated with the Incidence of Extensive Chronic Gvhd after Allogeneic BMT

Daisuke Koyama - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Cyclosporine eent

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Adriana Balduzzi - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

Evaluation of Healthcare Resource Utilization and Costs Among Patients with Chronic Myeloid Leukemia after Disease Progression

Elias Jabbour - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Parent-Reported and Self-Perceived Behavioral and Psychiatric Symptoms in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia

Wei Liu - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Hydrocortisone

JAK2 Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia

Elisabeth M.P. Steeghs - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Momelotinib

Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome

Wolthers Benjamin Ole - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute lymphoblastic leukemia

Asparaginase

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

Koji Sasaki - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Jessica I Hoell - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL)

Anthony V. Moorman - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Nirali N Shah - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

N/A

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Partow Kebriaei - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Busulfan

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Craig Speziali - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Koji Sasaki - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methotrexate

Filters

2187 Abstracts